Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "novel protein, PPM1J-RHOC readthrough" (ENSG00000271810) is a predicted protein coding gene in humans defined as a readthrough transcript between the PPM1J and RHOC loci on chromosome 1[1][2][9][7]. Readthrough (also called co-transcription or chimeric transcript) genes are typically formed when transcription extends across adjacent genes, producing an mRNA that encodes a hybrid or fused protein from the two parental genes. Such events are often computationally predicted based on RNA-seq data but may not be biologically significant or stably expressed[9][7]. There is no information on the endogenous protein product, expression, or function of this readthrough in the literature or major gene/protein databases, and it is not recognized as an established therapeutic target or disease biomarker. Data and annotations are derived primarily from gene prediction algorithms and automated genome annotation; caution is warranted in biological interpretation as the existence and biological role of this protein have not been experimentally confirmed[1][9][7]. Key point: This is not a well-characterized protein, receptor, or enzyme. It is a predicted, computationally-annotated readthrough transcript with no established function, disease association, or relevance as a therapeutic target. If looking for validated targets, PPM1J or RHOC themselves (as individual proteins/genes) are better-supported entities[4][11].
None characterized (No drugs, no mechanism defined)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel protein, PPM1J-RHOC readthrough.